Spera A, Pagliano P, Conti V
World J Hepatol. 2024; 16(5):661-666.
PMID: 38818300
PMC: 11135269.
DOI: 10.4254/wjh.v16.i5.661.
Talha K, Dayer M, Thornhill M, Tariq W, Arshad V, Tleyjeh I
Open Forum Infect Dis. 2022; 8(11):ofab479.
PMID: 35224128
PMC: 8864733.
DOI: 10.1093/ofid/ofab479.
Gobran S, Ancuta P, Shoukry N
Front Immunol. 2021; 12:726419.
PMID: 34456931
PMC: 8387722.
DOI: 10.3389/fimmu.2021.726419.
Ceasar R, Goldshear J, Brothers S, Wenger L, Kral A, Bluthenthal R
Int J Drug Policy. 2021; 97:103297.
PMID: 34077825
PMC: 9844096.
DOI: 10.1016/j.drugpo.2021.103297.
Mousavian G, Ghalekhani N, Tavakoli F, McFarland W, Shahesmaeili A, Sharafi H
Subst Abuse Treat Prev Policy. 2021; 16(1):29.
PMID: 33794943
PMC: 8017615.
DOI: 10.1186/s13011-021-00368-9.
Hepatitis C incidence and prevalence among Puerto Rican people who use drugs in New York City.
Arasteh K, Des Jarlais D, Feelemyer J, McKnight C
Glob Public Health. 2020; 15(12):1789-1799.
PMID: 32427534
PMC: 10204793.
DOI: 10.1080/17441692.2020.1768276.
Death after diagnosis of noncommunicable disease comorbid conditions, stratified by injection drug use.
Lesko C, Lau B, Chander G, Moore R
AIDS. 2018; 33(2):285-293.
PMID: 30325772
PMC: 6301107.
DOI: 10.1097/QAD.0000000000002054.
A Prospective Study to Investigate Predictors of Relapse among Patients with Opioid Use Disorder Treated with Methadone.
Naji L, Dennis B, Bawor M, Plater C, Pare G, Worster A
Subst Abuse. 2016; 10:9-18.
PMID: 27103815
PMC: 4827793.
DOI: 10.4137/SART.S37030.
The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.
Dennis B, Naji L, Bawor M, Bonner A, Varenbut M, Daiter J
Syst Rev. 2014; 3:105.
PMID: 25239213
PMC: 4171401.
DOI: 10.1186/2046-4053-3-105.
Genetic influence on methadone treatment outcomes in patients undergoing methadone maintenance treatment for opioid addiction: a pilot study.
Samaan Z, Bawor M, Dennis B, Plater C, Varenbut M, Daiter J
Neuropsychiatr Dis Treat. 2014; 10:1503-8.
PMID: 25187714
PMC: 4149396.
DOI: 10.2147/NDT.S66234.
Reducing HIV-related risk behaviors among injection drug users in residential detoxification.
Booth R, Campbell B, Mikulich-Gilbertson S, Tillotson C, Choi D, Robinson J
AIDS Behav. 2010; 15(1):30-44.
PMID: 20652630
PMC: 3023839.
DOI: 10.1007/s10461-010-9751-7.
A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design.
Jauffret-Roustide M, Le Strat Y, Couturier E, Thierry D, Rondy M, Quaglia M
BMC Infect Dis. 2009; 9:113.
PMID: 19607712
PMC: 2733898.
DOI: 10.1186/1471-2334-9-113.
Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them.
Roy K, Hutchinson S, Wadd S, Taylor A, Cameron S, Burns S
Epidemiol Infect. 2006; 135(3):433-42.
PMID: 16893486
PMC: 2870592.
DOI: 10.1017/S0950268806007035.
Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study).
Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, El-Guebaly N
J Urban Health. 2005; 82(2):250-66.
PMID: 15872194
PMC: 3456573.
DOI: 10.1093/jurban/jti049.
Hepatitis C and general practice: the crucial role of primary care in stemming the epidemic.
Budd J, Robertson R
Br J Gen Pract. 2005; 55(513):259-60.
PMID: 15826430
PMC: 1463125.
Using simulation for AIDS policy modeling: benefits for HIV/AIDS prevention policy makers in Vienna, Austria.
Rauner M
Health Care Manag Sci. 2002; 5(2):121-34.
PMID: 11993747
DOI: 10.1023/a:1014433117269.
Ignoring 'downstream infection' in the evaluation of harm reduction interventions for injection drug users.
Pollack H
Eur J Epidemiol. 2002; 17(4):391-5.
PMID: 11767966
DOI: 10.1023/a:1012790230000.
Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?.
Hope V, Judd A, Hickman M, Lamagni T, Hunter G, Stimson G
Am J Public Health. 2001; 91(1):38-42.
PMID: 11189821
PMC: 1446497.
DOI: 10.2105/ajph.91.1.38.
Minimising harm from hepatitis C virus needs better strategies.
Crofts N, Caruana S, Bowden S, Kerger M
BMJ. 2000; 321(7265):899.
PMID: 11021890
PMC: 1118695.
The impact of hepatitis C in general practice.
Singh S, Miller R, Madge S, Patch D
Br J Gen Pract. 2000; 50(456):532, 535-6.
PMID: 10954932
PMC: 1313746.
